Sirtuin-NAD Activator for Alzheimer's Disease

"Per information present on clinicaltrials.gov, this medical trial is still open for enrolment. The first posting was made December 1st 2021 and the last updates were applied July 11th 2022."

"Affirmative. The information on clinicialtrials.gov confirms that this trial is presently enrolling participants, which it began doing since December 1st 2021 and was last modified July 11th 2022. This medical study requires 50 individuals from a single centre to take part in the research."

"This clinical trial seeks to recruit 50 individuals, aged between 55 and 85, who have already been diagnosed with dementia. All potential participants must also possess a Mini-Mental State Exam score of 18-26 (inclusive), under 6 on the Geriatric Depression Scale 15 item version, an impaired memory performance below education adjusted cut off scores for Logical Memory II subscale delayed paragraph recall; adequate visual/auditory acuity; a Clinical Dementia Rating global score of 0.5 or 1; and be able to provide access to an informant (study partner) with regular contact that knows them well."

"Patients aged 55 to 85 are eligible for enrolment in this research. Additionally, there are 34 studies available for those younger than 18 and 750 trials suitable for people older than 65 years old."

"This 90-day trial is assessing the modification of βNMN concentrations in cerebrospinal fluid (CSF). Additional objectives focus on registering deviations from baseline to day 90 for NMN's metabolites, NAD levels in peripheral blood mononuclear cells using LC-MS/MS test protocols and biomarkers associated with aging including HbA1C, IGF1, T3, IL6, TNF-alpha and urinary F2-isoprostane."